Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Raw Materials: 2019-2025

Historic Raw Materials for Aytu Biopharma (AYTU) over the last 7 years, with Sep 2025 value amounting to $1.4 million.

  • Aytu Biopharma's Raw Materials rose 90.56% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 90.56%. This contributed to the annual value of $1.1 million for FY2025, which is 319.17% up from last year.
  • According to the latest figures from Q3 2025, Aytu Biopharma's Raw Materials is $1.4 million, which was up 23.05% from $1.1 million recorded in Q2 2025.
  • Over the past 5 years, Aytu Biopharma's Raw Materials peaked at $2.6 million during Q3 2021, and registered a low of $266,000 during Q2 2024.
  • For the 3-year period, Aytu Biopharma's Raw Materials averaged around $1.2 million, with its median value being $1.3 million (2023).
  • As far as peak fluctuations go, Aytu Biopharma's Raw Materials surged by 611.57% in 2021, and later plummeted by 79.55% in 2024.
  • Quarterly analysis of 5 years shows Aytu Biopharma's Raw Materials stood at $2.4 million in 2021, then decreased by 26.41% to $1.8 million in 2022, then decreased by 7.39% to $1.7 million in 2023, then plummeted by 70.13% to $494,000 in 2024, then spiked by 90.56% to $1.4 million in 2025.
  • Its last three reported values are $1.4 million in Q3 2025, $1.1 million for Q2 2025, and $537,000 during Q1 2025.